Diaceutics (DXRX.L) Stock Price

Diaceutics Price

LSE·CLOSED
1.52GBP-0.01 (-0.66 %)
Market closed

Over the last 8 years Diaceutics grew revenue by 27.6% annually, reaching 32.16 M GBP. Earnings per share have declined at 4.0% per year over the last 6 years. For Diaceutics, the net margin of -5.3% is down versus 2.1% a few years ago. The consensus 12-month price target for Diaceutics is 229.50 GBP, about 14,998.7% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 20% above its 52-week low.

Diaceutics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Diaceutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Diaceutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Diaceutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Diaceutics Stock Price History
DateDiaceutics Price
8/10/20261.52 GBP
8/7/20261.53 GBP
8/6/20261.50 GBP
8/5/20261.45 GBP
8/4/20261.44 GBP
7/31/20261.44 GBP
7/30/20261.33 GBP
7/29/20261.32 GBP
7/28/20261.27 GBP
7/27/20261.28 GBP
7/24/20261.29 GBP
7/23/20261.29 GBP
7/22/20261.32 GBP
7/21/20261.33 GBP
7/20/20261.33 GBP
7/17/20261.35 GBP
7/16/20261.35 GBP
7/15/20261.36 GBP
7/14/20261.41 GBP
7/13/20261.42 GBP
7/10/20261.43 GBP
7/9/20261.44 GBP
7/8/20261.43 GBP
7/7/20261.48 GBP
7/6/20261.47 GBP
7/3/20261.47 GBP
7/2/20261.46 GBP
7/1/20261.46 GBP
6/30/20261.46 GBP
6/29/20261.45 GBP
6/26/20261.45 GBP
6/25/20261.45 GBP
6/24/20261.45 GBP
6/23/20261.45 GBP
6/22/20261.49 GBP
6/19/20261.48 GBP
6/18/20261.46 GBP
6/17/20261.43 GBP
6/16/20261.43 GBP
6/15/20261.42 GBP
6/12/20261.43 GBP
6/11/20261.43 GBP
6/10/20261.43 GBP
6/9/20261.43 GBP
6/8/20261.43 GBP
6/5/20261.42 GBP
6/4/20261.44 GBP
6/3/20261.53 GBP
6/2/20261.45 GBP
6/1/20261.44 GBP
5/29/20261.43 GBP
5/28/20261.42 GBP
5/27/20261.48 GBP
5/26/20261.51 GBP
5/22/20261.67 GBP
5/21/20261.69 GBP
5/20/20261.69 GBP
5/19/20261.69 GBP
5/18/20261.69 GBP
5/15/20261.69 GBP
5/14/20261.70 GBP
5/13/20261.72 GBP
5/12/20261.72 GBP
5/11/20261.76 GBP
5/8/20261.77 GBP
5/7/20261.77 GBP
5/6/20261.74 GBP
5/5/20261.67 GBP
5/1/20261.66 GBP
4/30/20261.66 GBP
4/29/20261.73 GBP
4/28/20261.73 GBP
4/27/20261.75 GBP
4/24/20261.74 GBP
4/23/20261.74 GBP
4/22/20261.74 GBP
4/21/20261.64 GBP
4/20/20261.64 GBP
4/17/20261.65 GBP
4/16/20261.65 GBP
4/15/20261.65 GBP
4/14/20261.66 GBP
4/13/20261.66 GBP
4/10/20261.62 GBP
4/9/20261.62 GBP
4/8/20261.66 GBP
4/7/20261.62 GBP
4/2/20261.55 GBP
4/1/20261.57 GBP
3/31/20261.51 GBP
3/30/20261.46 GBP
3/27/20261.46 GBP
3/26/20261.46 GBP
3/25/20261.46 GBP
3/24/20261.43 GBP
3/23/20261.43 GBP
3/20/20261.44 GBP
3/19/20261.44 GBP
3/18/20261.46 GBP
3/17/20261.46 GBP
3/16/20261.46 GBP
3/13/20261.46 GBP
3/12/20261.47 GBP
3/11/20261.47 GBP
3/10/20261.46 GBP
3/9/20261.45 GBP
3/6/20261.46 GBP
3/5/20261.46 GBP
3/4/20261.43 GBP
3/3/20261.45 GBP
3/2/20261.49 GBP
2/27/20261.51 GBP
2/26/20261.51 GBP
2/25/20261.51 GBP
2/24/20261.51 GBP
2/23/20261.51 GBP
2/20/20261.50 GBP
2/18/20261.61 GBP
2/16/20261.65 GBP
2/13/20261.67 GBP
2/12/20261.65 GBP
2/9/20261.68 GBP
2/6/20261.66 GBP
2/5/20261.68 GBP
2/4/20261.67 GBP
2/3/20261.69 GBP
2/2/20261.72 GBP
1/30/20261.61 GBP
1/29/20261.65 GBP
1/28/20261.65 GBP
1/27/20261.68 GBP
1/26/20261.69 GBP
1/23/20261.70 GBP
1/22/20261.72 GBP
1/20/20261.59 GBP
1/19/20261.60 GBP
1/16/20261.60 GBP
1/15/20261.56 GBP
1/14/20261.42 GBP
1/13/20261.43 GBP
1/12/20261.41 GBP
1/9/20261.43 GBP
1/8/20261.43 GBP
1/7/20261.43 GBP
1/6/20261.38 GBP
1/5/20261.31 GBP
1/2/20261.27 GBP
12/31/20251.28 GBP
12/30/20251.27 GBP
12/29/20251.29 GBP
12/24/20251.29 GBP
12/23/20251.29 GBP
12/22/20251.28 GBP
12/19/20251.28 GBP
12/18/20251.29 GBP
12/17/20251.39 GBP
12/12/20251.39 GBP
12/11/20251.39 GBP
12/10/20251.40 GBP
12/9/20251.41 GBP
12/8/20251.43 GBP
12/5/20251.37 GBP
12/4/20251.36 GBP
12/3/20251.36 GBP
12/2/20251.38 GBP
12/1/20251.46 GBP
11/28/20251.51 GBP
11/27/20251.58 GBP
11/26/20251.59 GBP
11/25/20251.59 GBP
11/24/20251.62 GBP
11/21/20251.63 GBP
11/20/20251.64 GBP
11/19/20251.64 GBP
11/18/20251.64 GBP
11/17/20251.64 GBP
11/14/20251.64 GBP
11/13/20251.64 GBP
11/12/20251.65 GBP
11/11/20251.63 GBP
11/10/20251.64 GBP
11/7/20251.64 GBP
11/6/20251.61 GBP
11/5/20251.63 GBP
11/4/20251.61 GBP
11/3/20251.64 GBP
10/31/20251.68 GBP
10/30/20251.61 GBP
10/29/20251.64 GBP
10/28/20251.59 GBP
10/27/20251.61 GBP
10/24/20251.59 GBP
10/23/20251.60 GBP
10/22/20251.66 GBP
10/21/20251.65 GBP
10/20/20251.62 GBP
10/17/20251.62 GBP
10/16/20251.64 GBP
10/15/20251.64 GBP
10/14/20251.60 GBP
10/13/20251.62 GBP
10/10/20251.62 GBP
10/9/20251.62 GBP
10/8/20251.62 GBP
10/7/20251.62 GBP
10/6/20251.65 GBP
10/3/20251.65 GBP
10/2/20251.65 GBP
10/1/20251.65 GBP
9/30/20251.66 GBP
9/29/20251.63 GBP
9/26/20251.63 GBP
9/25/20251.63 GBP
9/24/20251.60 GBP
9/23/20251.59 GBP
9/22/20251.52 GBP
9/19/20251.50 GBP
9/18/20251.47 GBP
9/17/20251.45 GBP
9/16/20251.48 GBP
9/15/20251.48 GBP
9/12/20251.43 GBP
9/11/20251.42 GBP
9/10/20251.42 GBP
9/9/20251.40 GBP
9/8/20251.42 GBP
9/5/20251.43 GBP
9/4/20251.40 GBP
9/3/20251.41 GBP
9/2/20251.40 GBP
9/1/20251.38 GBP
8/29/20251.38 GBP
8/28/20251.38 GBP
8/27/20251.38 GBP
8/26/20251.38 GBP
8/25/20251.38 GBP
8/22/20251.38 GBP
8/21/20251.38 GBP
8/20/20251.38 GBP
8/19/20251.38 GBP
8/18/20251.38 GBP
8/15/20251.38 GBP
8/14/20251.38 GBP
Access this data via the Eulerpool API
Get Free API Key

Diaceutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
19.50 M GBP
575,000.00 GBP
724,000.00 GBP
Jan 1, 2023
23.70 M GBP
-3.02 M GBP
-1.75 M GBP
Jan 1, 2024
32.16 M GBP
-2.46 M GBP
-1.70 M GBP
Jan 1, 2025 (e)
38.44 M GBP
-633,318.00 GBP
93,412.00 GBP
Jan 1, 2026 (e)
46.74 M GBP
-770,185.00 GBP
797,993.24 GBP
Jan 1, 2027 (e)
56.32 M GBP
-928,019.00 GBP
3.21 M GBP
Jan 1, 2028 (e)
67.07 M GBP
-1.11 M GBP
7.14 M GBP
Jan 1, 2029 (e)
76.30 M GBP
-1.26 M GBP
10.85 M GBP

Diaceutics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 14, 2026, 12:44 AM
 
REVENUEM GBP
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM GBP
EBITM GBP
EBIT MARGIN%
NET INCOMEM GBP
NET INCOME GROWTH%
SHARESM
2016201720182019202020212022202320242025e2026e2027e2028e2029e
4.007.0010.0013.0012.0013.0019.0023.0032.0038.0046.0056.0067.0076.00
–75.0042.8630.00-7.698.3346.1521.0539.1318.7521.0521.7419.6413.43
50.0057.1460.0076.9275.0092.3184.2182.6187.5087.5087.5087.5087.5087.50
2.004.006.0010.009.0012.0016.0019.0028.0033.2540.2549.0058.6366.50
––1.002.00–––-3.00-2.00–––-1.00-1.00
––10.0015.38–––-13.04-6.25–––-1.49-1.32
–––––––-1.00-1.00––3.007.0010.00
––––––––––––133.3342.86
69.5869.5869.5864.1777.8384.9486.0984.2384.4584.4584.4584.4584.4584.45
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Diaceutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Diaceutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Diaceutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Diaceutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Diaceutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Diaceutics stock margins

The Diaceutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Diaceutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Diaceutics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
74.54 %
-2.13 %
2.07 %
Jan 1, 2021
87.73 %
3.94 %
4.02 %
Jan 1, 2022
85.83 %
2.95 %
3.71 %
Jan 1, 2023
83.15 %
-12.73 %
-7.37 %
Jan 1, 2024
87.91 %
-7.63 %
-5.30 %
Jan 1, 2025 (e)
87.91 %
-1.65 %
0.24 %
Jan 1, 2026 (e)
87.91 %
-1.65 %
1.71 %
Jan 1, 2027 (e)
87.91 %
-1.65 %
5.69 %

Diaceutics Stock Revenue, EBIT, Earnings per Share

The Diaceutics earnings per share therefore indicates how much revenue Diaceutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.16 GBP
-0.00 GBP
0.00 GBP
Jan 1, 2021
0.16 GBP
0.01 GBP
0.01 GBP
Jan 1, 2022
0.23 GBP
0.01 GBP
0.01 GBP
Jan 1, 2023
0.28 GBP
-0.04 GBP
-0.02 GBP
Jan 1, 2024
0.38 GBP
-0.03 GBP
-0.02 GBP
Jan 1, 2025 (e)
0.45 GBP
-0.01 GBP
0.00 GBP
Jan 1, 2026 (e)
0.55 GBP
-0.01 GBP
0.01 GBP
Jan 1, 2027 (e)
0.66 GBP
-0.01 GBP
0.04 GBP

Diaceutics business model & stock analysis

Diaceutics PLC is a consulting company specializing in optimizing diagnostic and treatment solutions for patients with serious and complex diseases. It was founded in 2005 by Peter Keeling in Belfast, Northern Ireland, and is now headquartered in London, UK. The company is listed on the London Stock Exchange and has offices in Europe, Asia, North America, and Australia. The business model of Diaceutics is based on the increasing number of personalized medicines on the market, targeting specific genetic markers to enable more accurate diagnosis and treatment. The company specializes in analyzing laboratory data to help doctors and pharmaceutical companies identify the specific tests needed for treating individual patients. It also offers a variety of services to optimize the use of tests in patient care. Diaceutics operates in three divisions: Diagnostic Services, Data and Analytics Services, and Strategy and Implementation Services. Diagnostic Services include optimizing diagnostic tests and identifying patient populations that would benefit from a particular treatment. Data and Analytics Services involve setting up data and analytics platforms to gain insights into the use of diagnostic tests in clinical practice. Strategy and Implementation Services support pharmaceutical companies in conducting campaigns to promote the use of diagnostic tests and increase the availability of personalized medicines. Diaceutics' products and services also include Diagnostic Insights products, providing insights into the use of diagnostic tests in various therapy areas. These insights help pharmaceutical companies optimize their personalization strategies and enhance the effectiveness of their medicines. The company also offers diagnostic programs aimed at promoting the use of diagnostic tests in clinical practice and eliminating barriers to the use of personalized medicines. Diaceutics has established partnerships with many of the world's leading diagnostic and pharmaceutical companies and also provides consulting services to support them in developing personalization strategies. Its clients include both pharmaceutical and diagnostic companies. Overall, Diaceutics has become a leading provider of personalized healthcare solutions. It occupies a unique position in the market by focusing on the intersection of diagnostics and therapy and being able to offer a wide range of products and services. Given the rapid progress in personalized medicine, Diaceutics will continue to play a significant role in optimizing diagnosis and treatment strategies and providing better care for patients.

Diaceutics SWOT Analysis

Strengths

Diaceutics PLC has several notable strengths which contribute to its success in the market:

  • 1. Established Reputation: Diaceutics PLC has built a strong reputation in the healthcare industry, known for its expertise in precision medicine diagnostics.
  • 2. Extensive Network: The company has a wide network of partnerships with leading pharmaceutical companies, diagnostic manufacturers, and laboratories, enabling it to access a large volume of data.
  • 3. Advanced Data Analytics: Diaceutics PLC leverages advanced analytics and artificial intelligence to extract valuable insights from complex diagnostic data, providing actionable recommendations to clients.
  • 4. Global Presence: With offices and operations in multiple countries, Diaceutics PLC has a global reach, allowing it to serve clients worldwide.

Weaknesses

Despite its strengths, Diaceutics PLC faces certain weaknesses that may pose challenges:

  • 1. Dependency on Partnerships: The company's success heavily relies on maintaining strong relationships with partners, which leaves it vulnerable to any changes in these partnerships.
  • 2. Limited Control over Data Sources: Diaceutics PLC's effectiveness is highly dependent on the quality and availability of data from various sources, which it may not have direct control over.
  • 3. Competitor Pressure: The precision medicine diagnostics market is highly competitive, with the emergence of new players, posing a risk to Diaceutics PLC's market share.

Opportunities

Diaceutics PLC can explore the following opportunities to drive future growth:

  • 1. Increasing Demand for Precision Medicine: As precision medicine gains wider adoption, there is an opportunity for Diaceutics PLC to expand its services and tap into new markets.
  • 2. Advancements in Diagnostic Technologies: Technological advancements in diagnostics provide an opportunity for Diaceutics PLC to innovate and offer new solutions that meet the evolving needs of clients.
  • 3. Strategic Partnerships: Collaborating with pharmaceutical companies and diagnostic manufacturers can enhance Diaceutics PLC's market presence and provide access to new data sources.

Threats

Diaceutics PLC should be mindful of the following threats that could impact its business:

  • 1. Regulatory Challenges: Evolving regulations and policies related to diagnostics and precision medicine may pose compliance and operational challenges for the company.
  • 2. Data Privacy and Security: The increasing emphasis on data privacy and security poses risks for Diaceutics PLC, as any breach could harm its reputation and undermine client trust.
  • 3. Economic Volatility: Global economic conditions may impact healthcare spending, potentially affecting demand for Diaceutics PLC's services.

Diaceutics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Diaceutics historical P/E ratio, EBIT multiple, and P/S ratio

Diaceutics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Diaceutics shares outstanding

The number of shares of Diaceutics was 84.45 M in 2025. This indicates how many shares Diaceutics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
77.83 M Stocks
Jan 1, 2021
84.94 M Stocks
Jan 1, 2022
86.09 M Stocks
Jan 1, 2023
84.23 M Stocks
Jan 1, 2024
84.45 M Stocks
Jan 1, 2025 (e)
84.45 M Stocks
Jan 1, 2026 (e)
84.45 M Stocks
Jan 1, 2027 (e)
84.45 M Stocks

Current Diaceutics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
12.50 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
2.30
Last Price
1.45
Currency
GBP
12M Return Potential
58.28 %
LTM Return
0 %

Diaceutics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
3/15/20240.01GBP-14.52 MGBP-2023 Q4
3/22/20220.01GBP-7.71 MGBP-2021 Q4

Diaceutics shareholder structure

% Name
18.54928%
Keeling (Peter)
Keeling (Peter)
16.27237%
Gresham House Asset Management Limited
Gresham House Asset Management Limited
9.19232%
Canaccord Genuity Wealth Management
Canaccord Genuity Wealth Management
6.40714%
Berenberg Bank (Asset Management)
Berenberg Bank (Asset Management)
4.72181%
Universal-Investment-Gesellschaft mbH
Universal-Investment-Gesellschaft mbH
3.97994%
Danske Bank Asset Management
Danske Bank Asset Management

Diaceutics Beneficial Ownership Filings (SEC 13D/G)

Free Float
57.5%
Float Shares
-
Shares Outstanding
-

Diaceutics Executives and Management Board

15 members · avg. age 50 · 47 % women

RK

Mr. Ryan Keeling

Chief Executive Officer, Executive Director · since 2024

541,475.00 GBP

Management

NR

Mr. Nick Roberts

Chief Financial Officer, Executive Director · since 2022

387,306.00 GBP
JC

Mr. Jordan Clark (40)

Chief Data Officer, Executive Director · since 2024

85,953.00 GBP
SB

Ms. Sandra Blake

Chief People Officer

–
LD

Ms. Lauren Dewitt

Executive Vice President, Legal, General Counsel, Group Company Secretary

–
MS

Ms. Marianna Sciortino

Vice President - Sales

–
AM

Ms. Amie Mcneice

Vice President - Marketing

–

Board of Directors

PK

Mr. Peter Keeling

Non-Executive Chairman of the Board · since 2024

234,010.00 GBP
GP

Mr. Graham Paterson (54)

Senior Independent Non-Executive Director

49,167.00 GBP
CM

Ms. Cheryl Macdiarmid (57)

Non-Executive Director

10,000.00 GBP

Diaceutics Supply Chain

Diaceutics Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
2 companies
#NameTrend
1
Gresham House
Supplier·Customer·Capital Markets·GB
-0.13
0.49
0.56
0.45
0.41
-0.66
2
Canaccord Genuity Group
Supplier·Customer·Capital Markets·CA
0.35
0.88
-0.55
-0.09
0
-0.60

Frequently asked questions about Diaceutics

The business model of Diaceutics PLC focuses on providing personalized diagnostics solutions and services to the pharmaceutical industry. Diaceutics helps pharmaceutical companies and laboratories optimize their diagnostic testing processes, ensuring patients receive accurate and timely test results. By harnessing real-world data and leveraging their expertise in diagnostic commercialization, the company enables precision medicine and improves patient outcomes. With a comprehensive approach that includes strategic consulting, data analytics, and software solutions, Diaceutics aims to bridge the gap between diagnostic testing and the delivery of targeted therapies.

Diaceutics PLC is primarily active in the healthcare and pharmaceutical industries. As a leading diagnostic commercialization company, Diaceutics specializes in helping pharmaceutical companies and laboratories improve patient outcomes through the delivery of precision medicine. With their extensive expertise in data analytics and laboratory network management, Diaceutics empowers healthcare providers to effectively integrate diagnostic testing into patient treatment pathways, thereby enhancing personalized medicine.

The main competitors of Diaceutics PLC in the market include companies such as LabCorp, QIAGEN, Foundation Medicine, and Genomic Health.

Diaceutics PLC is a leading data analytics and implementation services provider in the personalized medicine industry. Founded in 2005, the company has grown steadily and garnered a strong reputation for its expertise in diagnostic testing. It enables pharmaceutical companies, laboratories, and healthcare providers to optimize the use of targeted therapies for patients by leveraging advanced data analytics. Diaceutics PLC's robust platform helps bridge the gap between diagnostic testing and personalized medicine, significantly improving patient outcomes. With its deep industry knowledge and proprietary data-driven solutions, the company has become a trusted partner for life science companies globally, unlocking the potential of precision medicine.

Diaceutics PLC, a leading diagnostic data analytics and implementation services provider, has achieved several significant milestones. Firstly, the company successfully listed on the AIM market of the London Stock Exchange in March 2019, marking a major achievement in terms of financial market recognition. Additionally, Diaceutics has experienced substantial growth, expanding its global reach and establishing strategic partnerships with renowned pharmaceutical companies. Moreover, the company has received multiple awards and recognition for its innovative and impactful contributions to precision medicine. Diaceutics PLC's remarkable achievements are a testament to its commitment to revolutionizing the way healthcare providers utilize diagnostic testing, ultimately improving patient outcomes.

Diaceutics PLC is primarily present in multiple countries and regions worldwide. The company operates globally, with a strong presence in the United States, Europe, and key Asian markets. This includes countries such as the United Kingdom, Germany, France, Spain, Italy, China, Japan, and Australia, among others. With its expansive reach, Diaceutics PLC caters to healthcare providers, pharmaceutical companies, and diagnostic laboratories in various regions, enabling better personalized medicine and improving patient outcomes.

Diaceutics PLC represents a strong commitment to revolutionizing patient testing in the global diagnostic industry. The company's corporate philosophy is rooted in driving better patient outcomes by improving diagnostic testing for precision medicine. With a focus on leveraging data analytics and deep industry knowledge, Diaceutics PLC aims to bridge the gap between diagnostic testing and targeted therapies. By partnering with pharmaceutical companies, laboratories, and healthcare providers, Diaceutics PLC strives to enable faster and more accurate testing to ensure patients receive the right treatment at the right time. Through innovation, collaboration, and patient-centricity, Diaceutics PLC is dedicated to empowering precision medicine and transforming healthcare.

Analysts currently set an average price target of 223.89 GBP for the Diaceutics stock (median: 229.50 GBP), implying +54.4 % versus the latest price. The consensus is based on 9 analyst ratings.

Diaceutics Analyst Price Targets 2026

9 analysts currently rate the Diaceutics stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Diaceutics to generate revenue of 46.74 M GBP and earnings per share of 0.01 GBP.

Diaceutics Analyst Price Targets 2026

Converted at the current exchange rate, the Diaceutics share trades at 1.78 EUR (1.52 GBP).

The Diaceutics share (DXRX.L) is listed on 4 stock exchanges, including: Frankfurt (7DC.F), London (DXRX.L), London (DXRX.L).

Diaceutics PLC is an international company specializing in improving the diagnostics and care of cancer patients. The company's business model is based on the use of data analysis to understand the connections between diagnostics, therapy, and patient outcomes in order to optimize cancer treatment.

The expected revenue of Diaceutics is 46.74 M GBP. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Diaceutics is 797,993.24 GBP. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Diaceutics is currently 160.87. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Diaceutics stock.

The price-to-sales ratio (P/S) of Diaceutics is currently 2.75. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Diaceutics stock.

The Eulerpool Quality Score for Diaceutics is 1/10.

The ISIN of Diaceutics is GB00BJQTGV64. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Diaceutics is A2PF80. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Diaceutics is DXRX.L. The ticker symbol is used to trade Diaceutics shares on the stock exchange.

Diaceutics paid dividends every year for the past 0 years.

Diaceutics is assigned to the 'Health' sector.

The dividends of Diaceutics are distributed in GBP.

All fundamentals and in-depth analysis of Diaceutics

Our stock analysis for Diaceutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Diaceutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Diaceutics Stock
Diaceutics Revenue→
Diaceutics Stock
Diaceutics Net Income→
Diaceutics Stock
Diaceutics P/E→
Diaceutics Stock
Diaceutics P/S→
Diaceutics Stock
Diaceutics EBIT→
Diaceutics Stock
Diaceutics Dividend→
Diaceutics Stock
Diaceutics Directors Dealings→
Diaceutics Stock
Diaceutics Stocks→
Diaceutics Stock
Diaceutics Market capitalization→
Diaceutics Stock
Diaceutics Debt→
Diaceutics Stock
Diaceutics Liabilities→
Diaceutics Stock
Diaceutics Equity→
Diaceutics Stock
Diaceutics AAQS→
Diaceutics Stock
Diaceutics Employees→
Diaceutics Stock
Diaceutics ROE→
Diaceutics Stock
Diaceutics ROA→
Diaceutics Stock
Diaceutics ROCE→
Diaceutics Stock
Diaceutics News→
Diaceutics Stock
Diaceutics Analyst Price Targets→

Health Stocks

DiagnosDhruv WellnessDiagnos Laboratorium Utama PT TbkDhg Pharmaceutical Joint-StockDiagnostic Medical SystemsDhanvantri Jeevan RekhaDiagnosticos da AmericaDezhan Healthcare CoDiagnostykaDextech MedicalDiaMedica TherapeuticsDexcomAll Stocks A–Z →